AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00367094
Drug: Benazepril plus hydrochlorothiazide
RxNorm normalized name: benazepril / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02769247
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral naproxen vs placebo
Trial: NCT02769247
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: either normal saline or empty oral capsule
Trial: NCT03874897
Drug: CAR-CLDN18.2 T-Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2
Trial: NCT03626662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated volume to match experimental drug.
Trial: NCT00707304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, twice per day
Trial: NCT02714842
Drug: Radiolabelled Diclofenac Tablet A
RxNorm normalized name: diclofenac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed release diclofenac sodium tablet (50 mg)
Trial: NCT02714842
Drug: Radiolabelled Diclofenac tablet B
RxNorm normalized name: diclofenac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed release diclofenac sodium tablet (50 mg)
Trial: NCT02714842
Drug: Radiolabelled Diclofenac tablet C
RxNorm normalized name: diclofenac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed release diclofenac sodium tablet (25 mg)
Trial: NCT02714842
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enteric coated delayed release diclofenac sodium tablet (50 mg)
Trial: NCT03874897
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line systemic therapy according to physician's choice
Trial: NCT03965117
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
Trial: NCT00005839
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01978301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
Trial: NCT02844075
Drug: MK-3475(pembrolizumab)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery.
Trial: NCT01381887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
Trial: NCT01630083
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
Trial: NCT02142829
Drug: On-Q Pain Ball
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine HCl 0.25%
Trial: NCT02414841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04497155
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
Trial: NCT02006290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, matching placebo, QD
Trial: NCT04665284
Drug: Usual care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Trial: NCT00224419
Drug: CBT + NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
Trial: NCT02084446
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
Trial: NCT01242215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01242215
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03151603
Drug: Placebo to Arctuvan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of Placebo to Arctuvan
Trial: NCT00561821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet daily
Trial: NCT02084446
Drug: Sodium Mycophenolate
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
Trial: NCT02853084
Drug: HL2351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will be adjusted based on disease activities
Trial: NCT00385489
Drug: LXR-623
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00419471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
Trial: NCT00667043
Drug: remifentanil and propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Trial: NCT00667043
Drug: fentanyl and midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Trial: NCT02360956
Drug: Antihypertensive medication (per doctor suggestion)
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
Trial: NCT00047840
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00047840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04115293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection
Trial: NCT02282670
Drug: Stillen tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00549523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 0 mg bid (placebo)
Trial: NCT00549523
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 400 mg bid of L. frutescens.
Trial: NCT04245865
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2800 mg/m2 iv
Trial: NCT04245865
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2 orally daily for two weeks
Trial: NCT00549523
Drug: Mid Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 800 mg bid of L. frutescens.
Trial: NCT00549523
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 1200 mg bid of L. frutescens.
Trial: NCT01303887
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
Trial: NCT01303887
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
Trial: NCT02762890
Drug: Deep neuromuscular blockade
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
Trial: NCT02762890
Drug: Moderate neuromuscular blockade
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
Trial: NCT01704573
Drug: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA.
Trial: NCT00970333
Drug: [18F]-FEPPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
Trial: NCT02135146
Drug: Plasmalyte 3ml/kg/hr group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
Trial: NCT02135146
Drug: Plasmalyte 6ml/kg/hr group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
Trial: NCT03941431
Drug: Jueyin granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jueyin granules p.o. once a day for 8 weeks.
Trial: NCT03941431
Drug: Jueyin placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jueyin placebo granules p.o. once a day for 8 weeks.
Trial: NCT02982850
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03696186
Drug: Luminal type-1
RxNorm normalized name: WHITE SPIRIT TYPE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Trial: NCT03696186
Drug: Luminal type-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
Trial: NCT01631877
Drug: Enoxaparin with acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
Trial: NCT01086540
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Trial: NCT03696186
Drug: Neuroendocrine type-1
RxNorm normalized name: WHITE SPIRIT TYPE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Trial: NCT03696186
Drug: Neuroendocrine type-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Trial: NCT00439426
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Trial: NCT00226954
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03696186
Drug: Atypical type-1
RxNorm normalized name: WHITE SPIRIT TYPE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Trial: NCT03696186
Drug: Atypical type-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
Trial: NCT02015650
Drug: Mitomycin-C/ 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
Trial: NCT02404376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrevenous administration of Placebo
Trial: NCT02571543
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
Trial: NCT03211858
Drug: NovoLog/NovoRapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
Trial: NCT02466997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00276159
Drug: 852A
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
Trial: NCT00592280
Drug: Two-Layer Method pancreas preservation system drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
Trial: NCT02465814
Drug: Vilaprisan (BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 weeks),Vilaprisan (12 weeks)
Trial: NCT02465814
Drug: Vilaprisan (BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Trial: NCT03464552
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsule 3 hours before procedure
Trial: NCT03464552
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule 3 hours before procedure
Trial: NCT00203242
Drug: Depacon IV and Depakote ER
RxNorm normalized name: valproate Extended Release Oral Tablet [Depakote]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03449147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered orally BID
Trial: NCT01901757
Drug: HCP1201, Fasted followed by fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
Trial: NCT01901757
Drug: HCP1201, Fed followed by fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
Trial: NCT03602495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo Bid orally, continuously.
Trial: NCT00803374
Drug: AntiCD137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Trial: NCT00803374
Drug: AntiCD137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Trial: NCT00803374
Drug: AntiCD137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Trial: NCT00803374
Drug: AntiCD137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Trial: NCT00803374
Drug: AntiCD137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Trial: NCT02926846
Drug: Intravenous vancomycin & gentamicin with adjunctive lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Trial: NCT02926846
Drug: Intraperitoneal vancomycin & gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Trial: NCT01246518
Drug: MOB015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
Trial: NCT03523585
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
Trial: NCT02237950
Drug: 1% SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
Trial: NCT02237950
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Trial: NCT02380157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.